---

Peripartum (Postpartum) Cardiomyopathy - Complete Guide

---

1. Definition

• LVEF < 45% (some criteria also specify M-mode fractional shortening < 30%, or LV end-diastolic dimension > 2.7 cm/m²)
• Onset in the last month of pregnancy or up to 5 months postpartum
• Absence of pre-existing cardiac disease
• No other identifiable cause of HF (no valvular, ischemic, pericardial, or other cause)

---

2. Epidemiology

---

3. Risk Factors

• Older maternal age (> 30 years)
• African American / Black ethnicity
• Hypertensive disorders of pregnancy, including preeclampsia (~25% of PPCM cases have preeclampsia, vs. 5% background rate)
• Multifetal (twin or higher-order) pregnancies
• Increased parity (multiparity)
• Malnutrition
• Tocolytic therapy (particularly beta-mimetic agents like terbutaline)
• Obesity
• Fertility-assisted treatments

---

4. Pathophysiology

4a. Genetic Predisposition

• ~15% of PPCM cases carry TTN truncating variants (TTNtvs) - the same frequency seen in dilated cardiomyopathy (DCM)
• Variants also identified in TTNC1 and STAT3 genes
• TTN truncating mutations are associated with lower rates of LVEF recovery and a lower EF at 1-year follow-up
• PPCM may represent pregnancy acting as an environmental trigger for accelerated phenotypic expression of underlying genetic cardiomyopathy
• Genetic testing is recommended, as results impact both the mother and first-degree relatives

4b. Prolactin Pathway (Vasoinhibin Hypothesis)

• During late pregnancy, oxidative stress causes proteolytic cleavage of the 23-kDa nursing hormone prolactin into a 16-kDa proinflammatory fragment (vasoinhibin)
• This fragment impairs endothelial and cardiomyocyte function, reduces capillary density, and induces apoptosis
• This underpins the rationale for bromocriptine (a prolactin inhibitor) as a disease-specific therapy

4c. Antiangiogenic Imbalance

• The placenta secretes high levels of soluble fms-like tyrosine kinase 1 (sFlt-1), an inhibitor of VEGF
• sFlt-1 causes angiogenic imbalance and endothelial dysfunction
• High sFlt-1 levels predict worse clinical outcomes
• This mechanism is also shared with preeclampsia, explaining their co-occurrence

4d. Physiological Context

---

5. Clinical Presentation

• Dyspnea (especially exertional, orthopnea, paroxysmal nocturnal dyspnea)
• Leg edema - may be mistakenly attributed to normal pregnancy
• Fatigue and reduced exercise tolerance
• Chest discomfort or chest pain
• Palpitations (atrial and ventricular arrhythmias can occur)
• Tachycardia

• S3 gallop, elevated JVP, pulmonary crackles
• Peripheral edema
• Signs of low cardiac output (cold peripheries, hypotension in severe cases)

• Left ventricular thrombus and systemic embolism (stroke, limb ischemia) - especially with LVEF < 35%
• Ventricular arrhythmias and sudden cardiac death
• Cardiogenic shock
• Cardiopulmonary arrest
• Need for mechanical circulatory support or cardiac transplantation

---

6. Diagnosis

6a. Biomarkers

• BNP / NT-proBNP: Elevated levels strongly suggest cardiac dysfunction; if elevated, always proceed to echocardiography
• Troponin: Elevation indicates myocardial injury and predicts poor prognosis
• Both elevated NT-proBNP and troponin are predictors of poor outcome

6b. Electrocardiogram

• Non-specific; may show sinus tachycardia, ST-T changes, arrhythmias, or conduction abnormalities
• Important to rule out ischemia or arrhythmia

6c. Echocardiography (Diagnostic Standard)

• Diffuse LV systolic dysfunction with LVEF < 45%
• M-mode fractional shortening < 30%
• LV end-diastolic dimension > 2.7 cm/m²
• Absence of other structural causes (valvular disease, wall motion abnormalities suggesting ischemia)

• Right ventricular function
• Pulmonary pressures
• LV thrombus
• Pericardial effusion

6d. Cardiac MRI

• Useful in complex or uncertain cases
• Provides detailed assessment of both RV and LV function and dimensions
• Can differentiate PPCM from myocarditis, peripartum MI, or infiltrative disease
• Gadolinium is contraindicated during pregnancy; used only postpartum
• No pathognomonic MRI pattern exists for PPCM

6e. Coronary Evaluation

• Consider to exclude spontaneous coronary artery dissection (SCAD) - an important differential in peripartum women presenting with chest pain/HF

6f. Key Differentials to Exclude

• Pulmonary embolism
• Preeclampsia/eclampsia with pulmonary edema
• Valvular heart disease
• Myocarditis
• SCAD
• Tocolytic (terbutaline)-induced cardiomyopathy
• Pre-existing undiagnosed DCM

---

7. Management

7a. During Pregnancy (Antepartum)

• ACE inhibitors and ARBs - teratogenic (fetal renal toxicity, oligohydramnios)
• Sacubitril/valsartan - contraindicated
• Spironolactone - avoid (anti-androgenic effects); eplerenone also avoided
• Ivabradine - not recommended

7b. After Delivery (Postpartum) - Standard HF Therapy

7c. Bromocriptine (Disease-Specific Therapy)

• Targets the 16-kDa prolactin fragment (vasoinhibin) pathway
• Small trials, particularly from South Africa (Sliwa et al.), showed improved LVEF recovery
• A multicenter randomized trial (Eur Heart J 2017) showed benefit, particularly with 8-week vs. 1-week dosing
• The EORP PPCM registry 2025 (van der Meer et al., Eur Heart J 2025) reported improved outcomes with bromocriptine treatment
• Dose: 2.5 mg twice daily for 2 weeks, then 2.5 mg once daily for 6 weeks (standard protocol); or 1.25-2.5 mg once daily
• Requires concurrent anticoagulation (due to pro-thrombotic risk of prolactin suppression)
• 2025 ESC guidelines recommend considering it; still controversial per Braunwald's
• If not breastfeeding, bromocriptine is more easily used; a large randomized trial was ongoing as of Harrison's 22E

7d. Breastfeeding

• Previously prohibited (due to metabolic demand and prolactin stimulation)
• Currently generally encouraged in stable patients who can maintain fluid balance
• 2025 ESC guidelines suggest prevention of lactation should be considered in severe HF to reduce metabolic demand and enable safe use of standard HF medications

7e. Advanced/Refractory Heart Failure

• Intra-aortic balloon pump (IABP)
• Ventricular assist devices (VAD) - LVAD or biventricular
• Extracorporeal membrane oxygenation (ECMO) for cardiogenic shock
• Cardiac transplantation: PPCM accounts for ~5% of all female cardiac transplants in the US; it is the 4th most common cause of transplant in women; post-transplant outcomes are similar to other indications

7f. Arrhythmia Management

• Wearable cardioverter-defibrillator (WCD): Recommended for those with LVEF < 35% who are at risk for sudden death; ICD implantation is generally deferred until reassessment at 3-6 months (given potential for recovery)
• Implantable cardioverter-defibrillator (ICD): For persistent severe LV dysfunction after optimization

---

8. Predictors of Poor Outcome

---

9. Prognosis and Recovery

• 50-80% of patients in the US recover LVEF to ≥ 50% (Harrison's 22E cites 50-80%; Goldman-Cecil ~2/3)
• Most recovery occurs within 2-6 months of diagnosis; long-term trajectory is usually clear by 6 months postpartum
• ~1/3 have persistent LV dysfunction (LVEF < 45%) beyond 6 months
• Serial echocardiography is recommended at 1-3 month intervals
• Even patients with recovered LVEF remain at risk for recurrence and should continue surveillance
• The optimal duration of pharmacotherapy after LV recovery is unknown; medications should be weaned gradually with close monitoring

---

10. Subsequent Pregnancy

• 2025 ESC guidelines state that LVEF < 40% before a new pregnancy increases risk of LVEF deterioration, and subsequent pregnancy is discouraged in women with PPCM or DCM if LV function does not normalize
• Genetic testing should inform counseling - TTN mutation carriers have lower recovery rates and higher recurrence risk
• All women with a history of PPCM considering subsequent pregnancy should be managed by a multidisciplinary Pregnancy Heart Team
• Reliable contraception is essential until recovery is assessed

---

11. Genetic Counseling and Family Screening

• Genetic testing is now recommended in all PPCM cases - results impact both the mother and other family members
• Common findings: TTN truncating variants (~15%), STAT3, TTNC1 mutations
• A positive genetic test predicts less recovery and should prompt screening of first-degree relatives for subclinical DCM
• Among 90 DCM families, ~6% had at least one member with PPCM; genetic screening of PPCM relatives revealed undiagnosed DCM in multiple families

---

12. Labor and Delivery Considerations

• For women diagnosed before delivery: prompt delivery is typically recommended after maternal stabilization
• Delivery mode depends on obstetric indications; vaginal delivery is generally preferred if hemodynamically stable (reduced blood loss compared to cesarean)
• Neuraxial anesthesia is preferred - reduces afterload and sympathetic activation
• A Pregnancy Heart Team (cardiologist, maternal-fetal medicine, anesthesiologist) should be involved
• Hemodynamic monitoring and availability of mechanical support should be planned
• Perimortem cesarean may be required if the patient arrests

---

13. Prevention

• Optimize blood pressure and underlying cardiovascular disease before pregnancy
• Early vigilance for HF symptoms near term and postpartum
• Earlier diagnosis allows earlier treatment before severe deterioration
• In women with prior PPCM, careful preconception assessment is mandatory

---

14. Recent Evidence (2025)

---

Quick Reference Summary

---

• Harrison's Principles of Internal Medicine 22E (2025), pp. 2061-2062
• Fuster and Hurst's The Heart, 15th Edition, Chapter 51 (Elkayam & Pizula)
• Braunwald's Heart Disease, 12th Ed., Chapter 52
• Creasy & Resnik's Maternal-Fetal Medicine, Chapter 52
• Goldman-Cecil Medicine, Chapter 221
• Sliwa K et al. Peripartum cardiomyopathy. Lancet. 2025 [PMID: 41173010]
• Wang X et al. Risk Factors for PPCM: Systematic Review & Meta-Analysis. Heart Lung Circ. 2025 [PMID: 40701904]
• 2025 ESC Guidelines on Cardiovascular Diseases in Pregnancy